Patient Product Solution Manager
About the job
- A bachelor's degree or above in Business, Life Sciences, Pharmacy, Digital Health, Human-Computer Interaction, Health Informatics, or a related field is required.
- At least 5 years of professional experience in product management, digital health product development, or commercial strategy within pharmaceutical, biotech, or healthcare technology sectors is required.
- Demonstrated experience developing and launching digital products or patient engagement programs from concept through live product, including product design, user research, agile development, and product analytics, is required.
- A strong understanding of the pharmaceutical patient journey, chronic disease management, treatment adherence, and China's regulatory landscape for patient-facing digital health products is required.
- Familiarity with AI and machine learning tools, digital health platforms, customer relationship management systems, patient engagement technologies, and remote patient monitoring solutions is required.
- Strong analytical skills and a data-driven approach to product prioritization and decision-making are required, including experience with product analytics tools such as Mixpanel or Amplitude and A/B testing methodologies.
- Strong project management skills and the ability to manage multiple concurrent product workstreams, competing priorities, and diverse stakeholder groups are required.
- The ability to translate complex scientific and technical content into clear, patient-friendly messaging and executive presentations is required.
- Fluency in written and spoken English and Mandarin is required.
- A patient-first mindset, commercial acumen, and demonstrated interest in improving patient health outcomes and healthcare system innovation are required.
- Define and execute the patient product roadmap aligned with commercial priorities and AI innovation strategy, identifying opportunities to improve patient engagement, education, treatment adherence, and health outcomes through digital solutions.
- Develop product business cases and strategic proposals to secure senior leadership endorsement and cross-functional resource commitment.
- Lead end-to-end product development from opportunity identification and concept design through build, pilot, launch, scale, and iteration, using agile product development principles and stage-gate governance.
- Define product vision, user stories, acceptance criteria, and feature prioritization frameworks, collaborating with digital engineering, user experience design, medical, and commercial teams to deliver products that meet user needs and business objectives.
- Conduct and synthesize patient journey research, voice-of-patient studies, ethnographic research, and competitive market analysis to understand patient needs, pain points, information gaps, and behavioral drivers.
- Translate patient insights into actionable product requirements and design principles, ensuring product decisions are grounded in patient experience and validated with target users.
- Use artificial intelligence, machine learning, personalization engines, conversational artificial intelligence such as chatbots and virtual health assistants, and generative artificial intelligence to create scalable patient engagement solutions.
- Monitor emerging artificial intelligence technologies and digital health innovations for product applicability, and propose pilot initiatives to explore and validate new approaches.
- Partner with brand and marketing teams, medical affairs, regulatory and legal teams, compliance, information technology, patient advocacy, and external technology vendors and agencies to ensure products are scientifically sound, commercially impactful, and compliant.
- Serve as the patient product lead within cross-functional squads, facilitating alignment on scope, timelines, dependencies, and risk management across stakeholder groups.
- Define product key performance indicators, usage metrics, outcome measures, and patient satisfaction indicators; build analytics dashboards and reporting frameworks for performance monitoring and data-driven product decisions.
- Establish feedback loops, including user testing, patient advisory panels, and real-world evidence review, to continuously improve product features, usability, and health impact.
- Monitor patient digital product trends, competitive offerings, technology developments, and regulatory changes in pharmaceutical patient engagement, and identify opportunities for differentiation and innovation.
- Build and maintain an external intelligence network spanning technology partners, patient communities, academic institutions, and healthcare ecosystem players to inform product strategy.
- Ensure patient products comply with National Medical Products Administration regulations, Pfizer global product development standards, data privacy requirements including Personal Information Protection Law and General Data Protection Regulation principles, and applicable pharmaceutical promotional guidelines throughout the product lifecycle.
- Engage proactively with legal, compliance, and medical review processes to develop compliant-by-design products that maintain patient safety and data protection.
- Present product strategies, roadmap updates, performance results, and business case recommendations to senior leadership and cross-functional governance forums, and champion the patient perspective in commercial decision-making.
- Develop and maintain internal product documentation, including product briefs, roadmap decks, and feature specifications, to support cross-functional alignment and handoff.
- A master's degree is preferred.
- Direct experience with generative artificial intelligence product applications is a significant plus.
About the company
Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.
Company Size
10,001+
Company Stage
IPO
Headquarters
New York City, New York
Founded
1849
Get referred to Pfizer
See people who can refer or advise you
Simplify's Take
What believers are saying
- Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
- The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
- Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.
What critics are saying
- Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
- Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
- Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.
What makes Pfizer unique
- Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
- Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
- Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Relocation Assistance
Growth & Insights and Company News
6 month growth
-4%1 year growth
-3%2 year growth
-3%Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.
High dividend yields can hide weak payouts, and a four-step test helps separate real income from traps. It checks earnings with one-offs stripped out, full-year free cash flow against dividends, management's explanation, and whether debt funds the gap. Ford yields 4.99% and shows a trailing EPS of -$1.88, caused by $4.2B in one-time charges. Its debt-to-equity of 4.66 leaves the $0.60 dividend exposed to a downturn. Pfizer yields 6.03%, but its free cash flow yield is 5.60%. Clorox's roughly $405M of free cash flow fell short of about $601M in dividends. Whirlpool fails every step. It cut its quarterly dividend from $1.75 to $0.90 in 2025, paid no common dividend in the second quarter of 2026, and its shares are down 59.48% since the end of 2025. 3M and Dow pass, with payouts now covered by cash.
Four blue chip companies, UPS, Pfizer, Kraft Heinz, and Ford, may struggle to sustain their dividends, according to an analysis of their earnings, cash flow, and debt. UPS yields 7.02% and pays out about 121% of its GAAP earnings. Pfizer yields 6.10%, with a GAAP payout ratio of about 226%; its 2025 free cash flow of $9.076 billion fell short of $9.771 billion in dividends. Kraft Heinz yields 6.82%, but its trailing GAAP earnings per share are −$2.88 after $7.4 billion in impairments. Ford yields 4.98% after an $8.162 billion loss in 2025, and its debt-to-equity ratio is 4.66. All four companies say their payouts are safe, and each points to adjusted earnings guidance that covers the dividend.
The FDA has approved Pfizer's TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab for front-line maintenance treatment of adults with HER2-positive metastatic breast cancer. This chemotherapy-free option expands TUKYSA's use to an earlier disease stage. The approval follows Phase 3 HER2CLIMB-05 trial results showing median progression-free survival of 24.9 months versus 16.3 months with placebo—8.6 additional months without disease progression. The treatment reduced risk of progression or death by 35.9%. Most common adverse events included diarrhoea, musculoskeletal pain, hepatotoxicity, nausea, fatigue, rash, and vomiting. One fatal case of drug-induced liver injury occurred. TUKYSA was previously approved for second-line HER2-positive metastatic breast cancer treatment in 2020. HER2 is overexpressed in 15-20% of breast cancers.
Warren Buffett's favourite valuation metric, the ratio of total market capitalisation to GDP, has reached 235.8%, well above the 200% level he warned constitutes "playing with fire". The indicator sits near its record high from September 2026. Despite elevated overall market valuations, three stocks remain attractively priced. Enterprise Products Partners trades at 11.9 times forward earnings whilst offering a 6% distribution yield, benefiting from increased natural gas demand from AI data centres. JPMorgan Chase trades at 13.5 times forward earnings and could benefit from rising interest rates. Pfizer trades at just 9.7 times forward earnings with a 6.3% dividend yield, though it faces patent cliff challenges through 2028.